Get access

Azone® enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis

Authors

  • Allen Cato MD, PhD,

    1. From Cato Research Ltd., Durham, North Carolina, Colorado Dermatology Center, Denver, Colorado, Dermatology Association of Atlanta, Atlanta, Georgia, and Durham Pharmaceuticals Ltd., Durham, North Carolina
    Search for more papers by this author
  • James M. Swinehart MD,

    1. From Cato Research Ltd., Durham, North Carolina, Colorado Dermatology Center, Denver, Colorado, Dermatology Association of Atlanta, Atlanta, Georgia, and Durham Pharmaceuticals Ltd., Durham, North Carolina
    Search for more papers by this author
  • Edmond I. Griffin MD,

    1. From Cato Research Ltd., Durham, North Carolina, Colorado Dermatology Center, Denver, Colorado, Dermatology Association of Atlanta, Atlanta, Georgia, and Durham Pharmaceuticals Ltd., Durham, North Carolina
    Search for more papers by this author
  • Lynda Sutton BS,

    1. From Cato Research Ltd., Durham, North Carolina, Colorado Dermatology Center, Denver, Colorado, Dermatology Association of Atlanta, Atlanta, Georgia, and Durham Pharmaceuticals Ltd., Durham, North Carolina
    Search for more papers by this author
  • Allan S. Kaplan PhD

    1. From Cato Research Ltd., Durham, North Carolina, Colorado Dermatology Center, Denver, Colorado, Dermatology Association of Atlanta, Atlanta, Georgia, and Durham Pharmaceuticals Ltd., Durham, North Carolina
    Search for more papers by this author

Allen Cato, md, phd, Cato Research Ltd., 200 Westpark Corporate Center, 4364 S. Alston Ave., Durham, NC 27713
E-mail: aecato@cato.mail.com
Drug names, laurocapram: Azone®, TNX: Triamcinolone Acetonide/Azone®

Abstract

Abstract

Background  Atopic dermatitis is a chronic, relapsing condition affecting up to 14% of the population in Western countries. Topical corticosteroids are the mainstay of treatment. Triamcinolone acetonide, a corticoid of intermediate potency, has proven useful in the treatment of atopic dermatitis.

Aim  To evaluate the effectiveness of a triamcinolone acetonide–laurocapram combination in the treatment of atopic dermatitis.

Methods  One hundred and fifty patients were enrolled in a three-arm, parallel group, controlled clinical trial evaluating the effectiveness of a triamcinolone acetonide (0.05%) and laurocapram combination, applied twice daily for 2 weeks, in the treatment of atopic dermatitis. Fifty patients received triamcinolone acetonide–laurocapram (TNX), 50 triamcinolone acetonide (TN), and 50 a vehicle control formulation (AN). Response to treatment was evaluated by change in disease severity at 6 h, at 3, 8, and 15 days after the start of treatment, and by the global change in disease status.

Results  TNX effected a significantly higher degree of improvement in the signs and symptoms of atopic dermatitis (erythema, induration, and pruritus) and a greater overall improvement in disease status compared with treatment with TN or AN. Treatment-associated side-effects were local reactions, occurring in three, two, and six patients in the TNX, TN, and AN groups, respectively.

Conclusions  The results suggest that the incorporation of laurocapram in the formulation enhances the effectiveness of triamcinolone acetonide, without compromising its safety profile.

Ancillary